
Eisai prices Alzheimer's drug at $26,500, below partner Biogen's Aduhelm
Eisai and Biogen will price their new Alzheimer’s treatment Leqembi at $26,500 per year, US CEO Ivan Cheung tells Endpoints News. With outcries over the pricing of the drugmakers’ previous drug, Aduhelm, all eyes are on the sticker price for the duo’s new treatment cleared by the FDA on Friday.
Leqembi will likely be infused in few patients at this stage, as the US government’s insurer for those over the age of 65 puts a limit on coverage of anti-amyloid drugs following the Aduhelm nod. Patients essentially have to be in a clinical trial to get coverage from the Centers for Medicare & Medicaid Services.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.